TY - JOUR
T1 - Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma
T2 - A Fondazione Italiana Linfomi phase II study
AU - Iannitto, Emilio
AU - Luminari, Stefano
AU - Tripodo, Claudio
AU - Mancuso, Salvatrice
AU - Cesaretti, Marina
AU - Marcheselli, Luigi
AU - Merli, Francesco
AU - Stelitano, Caterina
AU - Carella, Angelo Michele
AU - Fragasso, Alberto
AU - Montechiarello, Elisa
AU - Ricciuti, Giuseppina
AU - Pulsoni, Alessandro
AU - Paulli, Marco
AU - Franco, Vito
AU - Federico, Massimo
PY - 2015/12/2
Y1 - 2015/12/2
N2 - Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.
AB - Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%). Of the 15 deaths, two occurred on treatment (one sepsis and one pneumonia). Six deaths were due to lymphoma progression, four to secondary neoplasia, one to sepsis, one to pneumonia and one to splenectomy complications. R-COMP should be restricted to patients with bulky disease associated with symptoms or to patients with possible histological transformation.
KW - first line
KW - rituximab
KW - Splenic marginal zone lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84948717353&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948717353&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1029925
DO - 10.3109/10428194.2015.1029925
M3 - Article
C2 - 25791121
AN - SCOPUS:84948717353
VL - 56
SP - 3281
EP - 3287
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 12
ER -